egfr inhibitors造句

例句与造句

1. Expression levels of cripto are associated with resistance to EGFR inhibitors.
2. New EGFR inhibitors include afatinib and dacomitinib.
3. Cetuximab and other EGFR inhibitors only work on tumors in which KRAS is not mutated.
4. This allows activation of the downstream effectors of EGFR even in the presence of an EGFR inhibitor.
5. Additional studies should confirm and further define its role in predicting EGFR inhibitors benefit . { { Cite journal
6. It's difficult to find egfr inhibitors in a sentence. 用egfr inhibitors造句挺难的
7. Little is known about the effects of EGFR inhibitors in SC, although some evidence suggests that these tumors are not likely to be highly responsive.
8. Studies have indicated that detection of KRAS gene mutations helps physicians identify patients that are unlikely to respond to treatment with targeted EGFR inhibitors, including cetuximab and panitumumab.
9. Epidermal growth factor receptor ( EGFR ) is another validated target in NSCLC . Additionally, the T790M  gatekeeper mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors.
10. The toxicity and safety of nimotuzumab have been assessed in several pre-clinical and clinical studies wherein it was noticed that side effects usually caused by EGFR inhibitors, especially rashes and other skin toxicities, were negligible.
11. The most common adverse effect of EGFR inhibitors, found in more than 90 % of patients, is a papulopustular rash that spreads across the face and torso; the rash's presence is correlated with the drug's antitumor effect.
12. While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native ( endogenous or unmutated ) EGFR . A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy.
13. Accordingly, genetic testing to confirm the absence of KRAS mutations ( and so the presence of the KRAS wild-type gene ), is now clinically routine before the start of treatment with EGFR inhibitors . mCRC patients with wild-type KRAS tumors have been shown to benefit from a response rate of over 60 % and a decreased risk for progression of over 40 % when treated with Erbitux as 1st-line therapy.